Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all5 continents, and responsible for a pandemic. France is the third most affected countryin Europe after Italy and Spain. Groups of patients at a higher risk of developing asevere form of COVID-19 have been defined: this include patients with immunosuppressivedisease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liverinjury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damageassociated with COVID-19 infection for compensated or decompensated cirrhotic patients.The objectives of this project are to estimate the incidence of COVID-19 inhepatocellular carcinoma population, both hospital and ambulatory, and to study theimpact on the frequency of severe forms, the prognosis, but also liver function, and themanagement of hepatocellular carcinoma, in this context of pandemic
Diagnostic Test: nasopharyngeal Covid 19 RT-PCR
nasopharyngeal Covid 19 RT-PCR
Inclusion Criteria:
- Patients with CHC and included in the French national prospective cohort CHIEF
- Hospital and ambulatory patients
- Infection confirmed by COVID-19 defined by a positive nasopharyngeal PCR or if PCR
COVID-19 negative : CT showing COVID-19 compatible pneumonia
- Suspected COVID-19 infection, not confirmed by COVID-19 PCR or chest CT, with no
other known cause of acute pneumonia.
Exclusion Criteria:
- Patient refusal
- Influenza only, confirmed by a diagnostic test
- Other proven causes of pneumonia and absence of COVID-19
CHU Amiens
Amiens, France